All In MedTech

Device Trial Radar · NCT04809285

Use of the Guardian™ Connect System With Smart Connected Devices

Last checked: Nov 20, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

217

Actual

Start

Apr 6, 2021

Primary completion

Sep 29, 2023

Study completion Sep 29, 2023

Sponsor

Lead sponsor
Medtronic MiniMed, Inc.Public (MDT)
Sponsor type
Industry
First posted
Mar 22, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 2 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect sensor, insulin, sleep, activity and food/meal data for a minimum of 90 days of device wear (Phase 1) and up to a maximum of 9 months of device wear (Phase 2) with optional insulin injection video capture and/or menstrual cycle tracking and/or cardiac monitoring in subjects with insulin requiring diabetes 2-80 years of age.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • Guardian™ Connect system, InPen™ Basal smart cap, smart insulin pens, and InPen™ Diabetes Management appDevice

    Guardian™ Connect system consists of Guardian™ Connect app, Guardian™ Connect transmitter, and Guardian Sensor (3), will be working with InPen™ Basal smart cap and smart insulin pens and InPen™ Diabetes Management app for multiple daily injections. The subject's insulin delivery, sleep, physical activity (as applicable), food intake data, and medication (as applicable) will be collected through applications with meal logging and medication requiring manual entry. In addition, subjects may also participate in optional self-administered insulin injection video capture and upload using a secure cloud-based site and/or monthly menstrual cycle logging using Apple Health and/or cardiac monitoring using BodyGuardian MINI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Time in HypoglycemiaTime frame: Day 1 to Day 90 in Phase 1 and Day 91 to up to 9 months in Phase 2
  2. Percentage of Time in EuglycemiaTime frame: Day 1 to Day 90 in Phase 1 and Day 91 to up to 9 months in Phase 2
  3. Percentage of Time in HyperglycemiaTime frame: Day 1 to Day 90 in Phase 1 and Day 91 to up to 9 months in Phase 2

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Arkansas Diabetes and Endocrinology Center

    Little Rock, Arkansas

  • Loma Linda University Medical Center

    Loma Linda, California

  • Mary and Dick Allen Diabetes Center

    Newport Beach, California

11 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.